Neuronetics, Inc. (NASDAQ:STIM – Get Rating) SVP William Andrew Macan sold 16,046 shares of the firm’s stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $5.96, for a total transaction of $95,634.16. Following the transaction, the senior vice president now owns 338,719 shares in the company, valued at approximately $2,018,765.24. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Neuronetics Stock Performance
Shares of STIM opened at $5.89 on Wednesday. The company has a market capitalization of $160.33 million, a PE ratio of -4.30 and a beta of 2.12. Neuronetics, Inc. has a one year low of $1.98 and a one year high of $6.95. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.02 and a quick ratio of 3.68. The company’s fifty day moving average price is $6.14 and its 200 day moving average price is $4.47.
Neuronetics (NASDAQ:STIM – Get Rating) last announced its earnings results on Tuesday, November 8th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.16. The firm had revenue of $16.50 million for the quarter, compared to the consensus estimate of $14.79 million. Neuronetics had a negative net margin of 58.85% and a negative return on equity of 49.80%. As a group, analysts expect that Neuronetics, Inc. will post -1.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of STIM. Y Intercept Hong Kong Ltd bought a new position in Neuronetics in the 2nd quarter worth $35,000. PDT Partners LLC acquired a new stake in Neuronetics in the 3rd quarter worth $38,000. Baker Tilly Wealth Management LLC acquired a new stake in Neuronetics in the 3rd quarter worth $40,000. CWM LLC acquired a new stake in Neuronetics in the 3rd quarter worth $41,000. Finally, Prudential Financial Inc. acquired a new stake in Neuronetics in the 3rd quarter worth $45,000. Institutional investors own 62.90% of the company’s stock.
Neuronetics, Inc commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients.
- Get a free copy of the StockNews.com research report on Neuronetics (STIM)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.